Hengsai Biological
About:
Hengsai Bio is a tumor immunotherapy developer that engages in R&D and industrialisation of a new generation dendritic cell tumor vaccines.
Top Investors: Zhongshan Venture Capital, TriWise Capital, Fuho Capital, Chengming Capital, Hengyu Group
Description:
Total Funding Amount:
100M CNY
Headquarters Location:
Guangdong, Jilin, China
Founded Date:
2018-01-01
Founders:
Number of Employees:
11-50
Last Funding Date:
2024-01-17
IPO Status:
Private
Industries:
© 2025 bioDAO.ai